Comparative Pharmacology
Head-to-head clinical analysis: MYMETHAZINE FORTIS versus PROMETH PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYMETHAZINE FORTIS versus PROMETH PLAIN.
MYMETHAZINE FORTIS vs PROMETH PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mymethazine fortis is a phenothiazine derivative that exerts antipsychotic and antiemetic effects primarily by blocking postsynaptic dopamine D2 receptors in the mesolimbic system, as well as possessing anticholinergic, antihistaminergic, and alpha-adrenergic antagonistic properties.
Antagonist at histamine H1 receptors; also exhibits anticholinergic, antiemetic, and sedative effects.
50 mg orally every 6 hours as needed for nausea and vomiting.
12.5-25 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life is 15-20 hours; in renal impairment (CrCl <30 mL/min), may extend to 30-40 hours, requiring dose adjustment.
Terminal elimination half-life is 10-14 hours in adults; may be prolonged in elderly or hepatic impairment.
Primarily renal (70-80% as unchanged drug and metabolites, with about 30% as unchanged); fecal (10-15%) via biliary elimination.
Primarily renal (approximately 70%) as metabolites and unchanged drug; biliary/fecal excretion accounts for ~20%.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine